Alkahest, Inc. products

Alkahest, with its partner Grifols, is developing lead clinical candidates, GRF6019 and GRF6021, as potential treatments for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease with cognitive impairment. Designed to safely replenish regenerative positive chronokines that decrease with age, GRF6019 and GRF6021 are highly selected human plasma fractions that provide enhancement of cognition and motor activity, reduction of inflammation and restoration of neurogenesis.

Another important detrimental chronokine to the biological process of aging is known as beta-2 microglobulin (B2M).

One the key chronokine targets identified using Alkahest’s platform is eotaxin. Eotaxin is an immunomodulatory chemokine that is increased in normal aging as well as multiple diseases of aging. It has been implicated in Alzheimer’s disease, Parkinson’s disease, retinal diseases and other aging-related diseases that involve systemic inflammation, demonstrating effects both in the CNS and in the periphery. Targeting this chronokine may cause improvements via two mechanisms—a broad anti-inflammatory mechanism and an immune modulatory mechanism through the body’s innate immune cells.